Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene editing therapies for high unmet need diseases ...

Precision BioSciences reports early PBGENE-HBV trial data showing safety and antiviral activity in chronic Hepatitis B patients, with more results expected in 2025.

Precision BioSciences (DTIL) announced initial results from the first administration of PBGENE-HBV in cohort 1, the lowest dose level of the ...

Assays for hepatitis B surface antigen (HBsAg) are the most frequently used tests to detect HBV infection. Vaccination for HBV can produce transiently detectable levels of HBsAg in patients.

HBV reactivation (HBVr) occurs when HBV activity is no longer suppressed by the immune system in people who are either positive for the HBV surface antigen (HBsAg) or HBV core antibody (anti-HBc).

HBsAg negative/anti-HB core antibody (HBc)-positive — and risk for reactivation based on the specific immunosuppressive therapies they received. For patients at high risk (>10%) for HBV ...

The Caloocan City government announced on Monday, Feb. 10, that it will offer a week-long free medical check-up at the ...

SG Americas Securities LLC grew its stake in shares of Arbutus Biopharma Co. (NASDAQ:ABUS – Free Report) by 30.7% during the fourth quarter, Holdings Channel reports. The institutional investor owned ...

We similarly followed 16 children of hepatitis B surface antigen (HBsAg)-positive mothers. Results: Of low risk infants receiving a plasma-derived vaccine, 41% (42 of 102) of those whose primary ...

The trial was tailored to evaluate the therapy at multiple ascending dose levels, with three dose administrations per level.